Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 11, 2026
Why Is Omada Health (OMDA) Stock Down -7.63% Today?

Why Is Omada Health (OMDA) Stock Down -7.63% Today?

Key Takeaways

  • OMDA shares fell 7.63% to $19.86, down $1.64 from the prior session's close of $21.50.
  • The decline extended a multiweek pullback that has carried the stock roughly 18% below its August highs.
  • Markets pointed to post–Investor Day profit-taking after long-term targets failed to sustain Thursday's early gains.
  • Elevated short interest and a steady stream of disclosed insider selling weighed on sentiment.
  • Broader weakness in growth-oriented digital health and healthcare technology names compounded the move.
  • Traders are now watching technical support near $20 and the company's next earnings report in early November.

Opening Summary

Omada Health, Inc. (OMDA), a South San Francisco–based provider of virtual care programs for chronic conditions such as diabetes, hypertension, and musculoskeletal issues, traded sharply lower on Friday. The stock dropped 7.63% to $19.86 during the session, compared with a prior closing price of $21.50, as investors took profits following the company's first Investor Day and a broader risk-off tone pressured smaller healthcare technology names.

Post–Investor Day "Sell the News"

The most direct catalyst behind the slide was a classic "sell the news" reaction. On Thursday, OMDA held its inaugural Investor Day and unveiled updated long-term financial targets, including annual revenue growth of at least 20%, an adjusted gross margin of 80%, and an adjusted EBITDA margin of 30%. Shares initially gained on the announcement but closed well off session highs, and that momentum reversed sharply on Friday as traders locked in gains after a run that had lifted the stock more than 40% year to date.

While the guidance signaled confidence in the company's enrollment and operating leverage, some investors interpreted the disclosures as already priced in following the stock's strong second-quarter earnings beat and raised full-year outlook in early August. The lack of a fresh, near-term catalyst left the shares vulnerable to selling pressure.

Insider Selling and Elevated Short Interest

Sentiment has also been tempered by a steady cadence of insider transactions. Chief Executive Sean Duffy and other executives sold shares under pre-arranged Rule 10b5-1 trading plans in recent weeks, filings show, a pattern that can weigh on investor confidence even when the sales are part of routine equity-management programs. At the same time, OMDA carries a relatively high short interest of roughly 13% of shares, amplifying downward moves when momentum turns negative.

Sector and Macro Pressure

The decline also reflected broader market conditions. Growth-oriented digital health and healthcare technology peers have faced renewed pressure amid a risk-off tone in equities, with concerns around inflation, interest rates, and elevated energy prices weighing on smaller, higher-multiple names. OMDA, as a recently profitable but still richly valued virtual-care provider, has been particularly sensitive to shifts in risk appetite, a dynamic that contributed to the stock's decline on Friday.

Market Context and Trading Activity

The move pushed OMDA decisively below the psychologically important $20 level and beneath its 50-day moving average, which has acted as resistance during the recent pullback. The shares remain well above their 200-day average and their 52-week low of $10.28, underscoring that the long-term trend is still intact despite the near-term correction. Trading activity was elevated relative to the stock's roughly 1.2 million share average daily volume, indicating conviction behind the sell-off rather than a quiet drift lower.

What Comes Next for OMDA

Looking ahead, investors will monitor whether OMDA can stabilize above key support levels and whether the company continues to convert its expanding membership base into durable revenue and margin growth. The next earnings report is expected in early November, with analysts maintaining a broadly positive stance and a consensus "Moderate Buy" rating, though expectations have been tempered by the recent slide. Key risks include execution on new channel partnerships, ongoing insider selling, and the broader market's appetite for growth equities in an uncertain macro environment.

Trending AI Robots

For traders seeking a more systematic approach to navigating volatile markets, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a filtered look at what is working right now. Explore the Trending AI Robots to see which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OMDA

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for OMDA turns negative, indicating new downward trend

OMDA saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator turned negative. In 16 of the 19 cases, the stock moved further down in the following days. The odds of a decline are at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

OMDA moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OMDA crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 3 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

The Aroon Indicator for OMDA entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OMDA's RSI Oscillator exited the oversold zone, 7 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for OMDA just turned positive on October 01, 2026. Looking at past instances where OMDA's MACD turned positive, the stock continued to rise in 9 of 9 cases over the following month. The odds of a continued upward trend are 90%.

Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMDA advanced for three days, in 70 of 83 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

OMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. OMDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.697) is normal, around the industry mean (7.432). P/E Ratio (28.955) is within average values for comparable stocks, (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.908) is also within normal values, averaging (6.065).

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.95B. The market cap for tickers in the group ranges from 708 to 45.33B. VEEV holds the highest valuation in this group at 45.33B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 2%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 28%. BEAT experienced the highest price growth at 59%, while TEM experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 70%. For the same stocks of the Industry, the average monthly volume growth was 117% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 74
Price Growth Rating: 52
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
OMDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
611 Gateway Boulevard
Phone
+1 888 987-8337
Employees
916
Web
https://www.omadahealth.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.
Why Is Omada Health (OMDA) Stock Down -7.63% Today?